University of Colorado, Denver

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Colorado, Denver sits in the top decile of US sponsors by registered trial count (#21 of 15,742 sponsors by registered trial count).

1,283 total trials 265 currently recruiting 830 completed early-phase tilt top decile by trial count

University of Colorado, Denver: 1,283 sponsored US clinical trials, 265 recruiting.

University of Colorado, Denver sponsors 1,283 registered US clinical trials on ClinicalTrials.gov, 265 of them currently recruiting, and 830 completed. 121 of these trials are in Phase 3-4 (later-stage) and 245 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 23 trials.

Top-decile sponsor footprint

University of Colorado, Denver ranks in the top decile of sponsors by registered trial count (#21 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 68/100

830 of 908 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,283 total, page 20 of 26

COMPLETED NA

Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity

NCT02043405

COMPLETED NA

Identifying and Treating Physical Function Impairment in Elders

NCT02044783

COMPLETED NA

Cognitive Dysfunction in Parkinson's Disease

NCT02346708

COMPLETED NA

Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress

NCT02037568

COMPLETED Phase 1

Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain

NCT02046434

COMPLETED Early Phase 1

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196

COMPLETED

Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy

NCT02012621

COMPLETED NA

Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults

NCT01997021

COMPLETED NA

Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program

NCT01985568

COMPLETED

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

NCT02132052

COMPLETED NA

Collaborative-care Rehabilitation After Dysvascular Amputation

NCT01929018

COMPLETED NA

Comparing Strategies for Translating Self-management Support Into Primary Care

NCT01945918

COMPLETED

Validation of Lower Body Negative Pressure (LBNP) Model of Human Hemorrhage in Trauma Patients

NCT01871909

COMPLETED NA

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01951339

COMPLETED Phase 2

Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study

NCT01968135

TERMINATED NA

Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry

NCT01971853

COMPLETED Phase 2

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

NCT01935336

COMPLETED

Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium

NCT02288429

COMPLETED

A New Approach to Measuring Energy Expenditure in Humans

NCT01938794

COMPLETED Phase 2

Effectiveness of Therapy Via Telemedicine Following Cochlear Implants

NCT02497690

TERMINATED

Evaluation of Potential Allergenicity of New Soybean Varieties

NCT01950559

COMPLETED NA

Cognitive Dysfunction In Parkinson's

NCT02468804

COMPLETED NA

Impact of Prophylactic High Flow Nasal Oxygen in Post-Operative Thoracic Surgical Patients

NCT03024112

COMPLETED NA

Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet

NCT02208622

COMPLETED Phase 1

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

NCT01916577

COMPLETED NA

Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)

NCT01920152

COMPLETED Phase 3

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01853553

COMPLETED Phase 2

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

NCT02474901

TERMINATED Phase 2

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

NCT01845792

TERMINATED Phase 2

Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

NCT01917318

COMPLETED Early Phase 1

Study of the Effect of GM-CSF on Macrophages in Ependymoma

NCT04408092

COMPLETED NA

Culturally Grounded Early Substance Use Prevention for American Indian Families

NCT02383225

COMPLETED NA

Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

NCT01883804

COMPLETED Phase 2

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

NCT01859390

COMPLETED NA

Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia

NCT02647437

TERMINATED Phase 1

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

NCT01851603

COMPLETED NA

Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals

NCT02347527

TERMINATED Phase 4

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

NCT01838174

COMPLETED Phase 2

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

NCT01841333

COMPLETED

Evaluating Color Perception Under LED Red/Green and Green Dominant Light

NCT01927536

COMPLETED

Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy

NCT01869218

COMPLETED NA

Effects of Estrogen Deficiency on Energy Expenditure

NCT01846728

COMPLETED Phase 4

Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

NCT01701583

COMPLETED

Pain Phenotypes in Knee Osteoarthritis

NCT02664896

COMPLETED Early Phase 1

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400

COMPLETED NA

Functional Prehabilitation and Major Elective Surgery

NCT01943773

COMPLETED NA

Intervention to Increase Parent-provider Communication During Referrals

NCT01797497

COMPLETED

Genetic Studies in Patients and Families With Infantile Spasms

NCT01723787

COMPLETED Phase 3

EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes

NCT01808690

COMPLETED

Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

NCT01404728

← Previous Page 20 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 114
Phase 2 131
Phase 3 37
Phase 4 84

What is open in the University of Colorado, Denver pipeline

265 recruiting of 1,283 indexed (21% open); 830 completed (65%).

Phase mix: 121 late (III/IV) vs 245 early (I/II) (early-phase heavy).

Top condition: Obesity (23 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Colorado, Denver: open-pipeline peers nationwide

Peers matched on 1,283 registered trials and 21% open enrollment, not the therapeutic-area sidebar.

University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20%25% Total trials Recruiting share University of Colorado, DenverAstraZenecaUniversity of MichiganUniversity of PittsburghEli Lilly and CompanyCedars-Sinai Medical CenterCraig HospitalW.L.Gore & AssociatesGeorgia Institute of Technology
University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,283 trials (± recruiting share)

Sponsors near 21% open enrollment (± trial volume)

What to do with this University of Colorado, Denver page

1,283 registered trials is a research-attention snapshot, not an endorsement of University of Colorado, Denver or any single study.

  • 265 of University of Colorado, Denver's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Colorado, Denver studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Colorado, Denver pipeline card: 1,283 registered trials from official public datasets.Report a data error.